For the past decade, fusion, cage or not, has been the gold standard in spine surgery. Now, a handful of companies, including Seattle-based Spinal Dynamics, is betting that fusion will be replaced by joint replacement, in this case artificial disc replacement, in spine surgery just as it did in total hip and knee surgery many years ago. Spinal Dynamics' main challenge lies in overcoming surgeon skepticism, especially in cervical procedures where fusions are common and very successful. And to help, they've lined up a distribution agreement with spine market leader Medtronic Sofamor Danek.
by David Cassak
As we noted last month, spine instruments and implants are the orthopedic industry's version of a 20-year overnight success. Today,...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
